Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J. Grunberg S, et al. Among authors: herrstedt j. J Clin Oncol. 2011 Apr 10;29(11):1495-501. doi: 10.1200/JCO.2010.31.7859. Epub 2011 Mar 7. J Clin Oncol. 2011. PMID: 21383291 Clinical Trial.
Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer.
Ballatori E, Roila F, De Angelis V, Ciccarese G, Palladino MA, Tonato M, Del Favero A, Herrstedt J, Dicato M, du Bois A, Hesketh P, Kris M, Gralla RJ. Ballatori E, et al. Among authors: herrstedt j. Support Care Cancer. 1997 Jul;5(4):269-73. doi: 10.1007/s005200050073. Support Care Cancer. 1997. PMID: 9257422
Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ. de Wit R, et al. Among authors: herrstedt j. J Clin Oncol. 2003 Nov 15;21(22):4105-11. doi: 10.1200/JCO.2003.10.128. Epub 2003 Oct 14. J Clin Oncol. 2003. PMID: 14559891 Clinical Trial.
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ. de Wit R, et al. Among authors: herrstedt j. Eur J Cancer. 2004 Feb;40(3):403-10. Eur J Cancer. 2004. PMID: 14746859 Clinical Trial.
Delayed emesis: moderately emetogenic chemotherapy.
Roila F, Warr D, Clark-Snow RA, Tonato M, Gralla RJ, Einhorn LH, Herrstedt J. Roila F, et al. Among authors: herrstedt j. Support Care Cancer. 2005 Feb;13(2):104-8. doi: 10.1007/s00520-004-0700-8. Epub 2004 Nov 12. Support Care Cancer. 2005. PMID: 15549426 Review.
Acute emesis: moderately emetogenic chemotherapy.
Herrstedt J, Koeller JM, Roila F, Hesketh PJ, Warr D, Rittenberg C, Dicato M. Herrstedt J, et al. Support Care Cancer. 2005 Feb;13(2):97-103. doi: 10.1007/s00520-004-0701-7. Epub 2004 Nov 23. Support Care Cancer. 2005. PMID: 15565276 Review.
195 results